Immusoft: Immusoft reports positive data from trial of mucopolysaccharidosis type I therapy
Immusoft has reported positive results from a Phase I trial of ISP-001, which is designed to treat mucopolysaccharidosis type I. The post Immusoft reports positive data from trial of mucopolysaccharidosis type I therapy appeared first on Clinical Trials Arena.
Read full article »
Immusoft is a Washington-based clinical-stage biotechnology company that researches and develops novel therapies for the treatment of genetic diseases.
Read more